NIPU: a Randomised, Open-Label, Phase II Study Evaluating Nivolumab and Ipilimumab Combined with UV1 Vaccination As Second Line Treatment in Patients with Malignant Mesothelioma
Journal of Translational Medicine（2021）
关键词
Malignant pleural mesothelioma,Telomerase vaccine,Immunotherapy,hTERT,Nivolumab,Ipilimumab,Biomarker,Immune response
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要